Formulation And In Vitro Characterisation Of Gemifloxacin Floating Tablets

Abstract

The present study was aimed to formulate and evaluate floating tablets of Gemifloxacin by direct compression method. Gemifloxacin is used as aoral broad-spectrum quinolone antibacterial agent used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. Gemifloxacin is stable in neutral or slightly acidic media. In this study, excipients like Eudragit RSPO, HPMC, Carbopol 974P, sodium bicarbonate and Citric acid were incorporated in a nine different concentrations (F1-F9) along with other excipients (Magnesium Stearate, Talc and Micro crystalline cellulose) to formulate floating tablets by direct compression method. Then all the nine formulations were evaluated for uniformity of weight, hardness, thickness, friability test, floating lag time, drug content and dissolution studies. The dissolution profile of trial-7 (formulation 7) was observed to be better than other formulations. In trial-7Gemifloxacin was formulated as a floating tablet by using Carbopol 974P (32.5 mg) as a matrix forming polymer and sodium bi carbonate (10 mg) as a gas generating agent. Trial-7 formulation showed a good dissolution profile for a controlled period of time which was noticed to be as 99.29% at the end of 12th hour. Thus, it can be concluded that the floating drug delivery system of Gemifloxacin using the appropriate polymers in right amount may enhance the activity ofthe drug by prolonging the gastric residence time or reducing the floating lag time.